{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T15:15:53Z","timestamp":1648826153637},"reference-count":25,"publisher":"Japan Society for Clinical Immunology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2177\/jsci.37.468","type":"journal-article","created":{"date-parts":[[2015,2,14]],"date-time":"2015-02-14T22:05:50Z","timestamp":1423951550000},"page":"468-474","source":"Crossref","is-referenced-by-count":0,"title":["Topics of neuromyelitis optica"],"prefix":"10.2177","volume":"37","author":[{"given":"Katsuichi","family":"MIYAMOTO","sequence":"first","affiliation":[{"name":"Department of Neurology, Kinki University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) Warabi, Y., et al.: Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. <i>J Neurol Sci<\/i>. <b>252<\/b>: 57-61, 2007."},{"key":"2","unstructured":"2) Chihara, N., et al.: Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. <i>Proc Natl Acad Sci U S A<\/i>. <b>108<\/b>: 3701-3706, 2011."},{"key":"3","doi-asserted-by":"publisher","unstructured":"3) Wingerchuk, D.M., et al.: Revised diagnostic criteria for neuromyelitis optica. <i>Neurology<\/i>. <b>66<\/b>: 1485-1489, 2006.","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"4","unstructured":"4) Wingerchuk, D.M., et al.: The spectrum of neuromyelitis optica. <i>Lancet Neurol<\/i>. <b>6<\/b>: 805-815, 2007."},{"key":"5","unstructured":"5) Kitley, J., et al.: Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. <i>Brain<\/i>. <b>135<\/b>: 1834-1849, 2012."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6) Sato, D.K., et al.: Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. <i>Neurology<\/i>. <b>80<\/b>: 2210-2216, 2013.","DOI":"10.1212\/WNL.0b013e318296ea08"},{"key":"7","doi-asserted-by":"crossref","unstructured":"8) Fujihara, K.: Neuromyelitis optica and astrocytic damage in its pathogenesis. <i>J Neurol Sci<\/i>. <b>306<\/b>: 183-187, 2011.","DOI":"10.1016\/j.jns.2011.02.018"},{"key":"8","doi-asserted-by":"crossref","unstructured":"9) Wingerchuk, D.M., Weinshenker, B.G.: Neuromyelitis optica. <i>Curr Treat Options Neurol<\/i>. <b>10<\/b>: 55-66, 2008.","DOI":"10.1007\/s11940-008-0007-z"},{"key":"9","unstructured":"11) Kimbrough, D.J., et al.: Treatment of Neuromyelitis Optica: Review and Recommendations. <i>Mult Scler Relat Disord<\/i>. <b>1<\/b>: 180-187, 2012."},{"key":"10","unstructured":"12) Kageyama, T., et al.: Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. <i>J Neurol<\/i>. <b>260<\/b>: 627-634, 2013."},{"key":"11","doi-asserted-by":"crossref","unstructured":"13) Miyamoto, K., Kusunoki, S.: Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. <i>Ther Apher Dial<\/i>. <b>13<\/b>: 505-508, 2009.","DOI":"10.1111\/j.1744-9987.2009.00780.x"},{"key":"12","unstructured":"14) The Multiple Sclerosis International Federation: Epidemiology of MS. <i>MS Atlas 2013<\/i>. 8-11, 2013."},{"key":"13","unstructured":"16) Bettelli, E., et al.: Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. <i>J Clin Invest<\/i>. <b>116<\/b>: 2393-2402, 2006."},{"key":"14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4236\/oji.2013.32007","volume":"3","year":"2013","unstructured":"17) Moriguchi, K., et al.: Autoantibodies against myelin antigens in patients with neuromyelitis optica. <i>Open Journal of Immunology<\/i>. <b>3<\/b>: 41-46, 2013.","journal-title":"Open Journal of Immunology","ISSN":"http:\/\/id.crossref.org\/issn\/2162-450X","issn-type":"print"},{"key":"15","doi-asserted-by":"publisher","unstructured":"18) Sato, D.K., et al.: Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. <i>Neurology<\/i>. <b>82<\/b>: 474-481, 2014.","DOI":"10.1212\/WNL.0000000000000101"},{"key":"16","unstructured":"19) Jacob, A., et al.: Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. <i>Arch Neurol<\/i>. <b>65<\/b>: 1443-1448, 2008."},{"key":"17","unstructured":"20) Nakashima, I., et al.: Anti-aquaporin 4 antibodies increase transiently after rituximab treatment in neuromyelitis optical with an association of B cell activating factor. <i>Neurology<\/i>. <b>74<\/b>: A168, 2010."},{"key":"18","unstructured":"21) Sanchez-Carteyron, A., et al.: Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica. <i>Neurology<\/i>. <b>74<\/b>: 1471-1473, 2010."},{"key":"19","unstructured":"22) Uzawa, A., et al.: CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. <i>J Neurol Neurosurg Psychiatry<\/i>. <b>83<\/b>: 339-340, 2012."},{"key":"20","doi-asserted-by":"publisher","unstructured":"23) Araki, M., et al.: Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. <i>Neurology<\/i>. <b>82<\/b>: 1302-1306, 2014.","DOI":"10.1212\/WNL.0000000000000317"},{"key":"21","unstructured":"24) Hinson, S.R., et al.: Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. <i>Proc Nat Acad Sci<\/i>. <b>109<\/b>: 1245-1250, 2012."},{"key":"22","unstructured":"25) Kuroda, H., et al.: Increase of complement fragment C5a in cerebrospinal fluid during exacerbation of neuromyelitis optica. <i>J Neuroimmunol<\/i>. <b>254<\/b>: 178-182, 2013."},{"key":"23","unstructured":"26) Russell, R.P., et al.: Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Nat Biotechnol<\/i>. <b>25<\/b>: 1256-1264, 2007."},{"key":"24","unstructured":"27) Pittock, S.J., et al.: Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. <i>Lancet Neurol<\/i>. <b>12<\/b>: 554-562, 2013."},{"key":"25","unstructured":"28) Hillmen, P., et al.: Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. <i>Am J Hematol<\/i>. <b>85<\/b>: 553-559, 2010."}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u8996\u795e\u7d4c\u810a\u9ac4\u708e\u306e\u6700\u8fd1\u306e\u8a71\u984c"],"language":"en","deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T05:34:04Z","timestamp":1498196044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/37\/6\/37_468\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.37.468","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}